The efficacy in pediatric acute myeloid leukemia ( AML ) of single-agent methotrexate ( MTX ) at a higher dose than previously applied , 1,000 mg/m2 , given as a theoretically beneficial 36-hr continuous infusion , is unknown , but may be beneficial based on preclinical data .
